[HTML][HTML] Direct cardiac effects of SGLT2 inhibitors
S Chen, R Coronel, MW Hollmann, NC Weber… - Cardiovascular …, 2022 - Springer
Abstract Sodium-glucose-cotransporter 2 inhibitors (SGLT2is) demonstrate large
cardiovascular benefit in both diabetic and non-diabetic, acute and chronic heart failure …
cardiovascular benefit in both diabetic and non-diabetic, acute and chronic heart failure …
Potential roles of sodium‐glucose co‐transporter 2 inhibitors in attenuating cardiac arrhythmias in diabetes and heart failure
T Attachaipanich, SC Chattipakorn… - Journal of Cellular …, 2022 - Wiley Online Library
Abstract Sodium‐glucose co‐transporter 2 (SGLT‐2) inhibitors are antidiabetic drugs that
have been shown to exert cardiovascular benefits. Their benefits including a reduction of …
have been shown to exert cardiovascular benefits. Their benefits including a reduction of …
Sodium-glucose cotransporter 2 inhibitors in patients with heart failure: a systematic review and meta-analysis of randomized trials
Y Ahmad, MV Madhavan, GW Stone… - … Journal-Quality of …, 2022 - academic.oup.com
Aims Sodium-glucose cotransporter 2 (SGLT-2) inhibitors have now been evaluated for the
treatment of heart failure in several placebo-controlled randomized controlled trials (RCTs) …
treatment of heart failure in several placebo-controlled randomized controlled trials (RCTs) …
[HTML][HTML] Antiarrhythmic effects and mechanisms of sodium-glucose cotransporter 2 inhibitors: A mini review
J Wu, Y Liu, X Wei, X Zhang, Y Ye, W Li… - Frontiers in …, 2022 - frontiersin.org
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a new type of oral hypoglycaemic
agent with good cardiovascular protective effects. There are several lines of clinical …
agent with good cardiovascular protective effects. There are several lines of clinical …
Evaluation of toxic effects of dapagliflozin on reproductive system in diabetic rats
B Karaca, T Boran, AK Köroğlu… - Turkish Journal of …, 2022 - journals.tubitak.gov.tr
Background/aim: Dapagliflozin (DAPA), sodium-glucose cotransporter 2 (SGLT2) inhibitor, is
an insulin-independent antidiabetic drug used to control hyperglycaemia by promoting …
an insulin-independent antidiabetic drug used to control hyperglycaemia by promoting …
[PDF][PDF] 钠-葡萄糖共转运体2 型抑制剂与心律失常的关系及进展
吴金春， 刘韬， 黄从新 - 临床心血管病杂志, 2022 - whuhzzs.com
钠-葡萄糖共转运体2型抑制剂与心律失常的关系及进展∗ Page 1 2022,38 临床心血管病杂志 (8):675-679
JournalofClinicalCardiology(China) 引用本文:吴金春,刘韬,黄从新.钠-葡萄糖共转运体2型抑制 …
JournalofClinicalCardiology(China) 引用本文:吴金春,刘韬,黄从新.钠-葡萄糖共转运体2型抑制 …
The relationship and research progress of sodium glucose cotransporter 2 inhibitors and arrhythmia
WU Jinchun, LIU Tao, H Congxin - J Clin Cardiol, 2022 - en.whuhzzs.com
Sodium-glucose cotransporter 2 inhibitor (SGLT2i) is a novel type of oral hypoglycemic
agent with cardiovascular and renal protection. SGLT2i has also been found to have anti …
agent with cardiovascular and renal protection. SGLT2i has also been found to have anti …
Akute Effekte von Palmitoleat auf die Ca2+-Homöostase ventrikulärer Kardiomyozyten
T Guthof - 2022 - refubium.fu-berlin.de
Ziele: Erhöhte Serumkonzentrationen von Palmitoleat sind mit einem erhöhten
Herzinsuffizienzrisiko assoziiert. In der vorliegenden Arbeit wurden die Effekte von …
Herzinsuffizienzrisiko assoziiert. In der vorliegenden Arbeit wurden die Effekte von …